Gradient Investments LLC lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM – Get Rating) by 329.4% during the second quarter, Holdings Channel reports. The fund owned 131,448 shares of the medical device company’s stock after acquiring an additional 100,834 shares during the period. Gradient Investments LLC’s holdings in DexCom were worth $9,797,000 as of its most recent SEC filing.
Other large investors have also modified their holdings of the company. Jennison Associates LLC grew its stake in shares of DexCom by 83.4% during the first quarter. Jennison Associates LLC now owns 2,600,283 shares of the medical device company’s stock worth $1,330,305,000 after purchasing an additional 1,182,632 shares in the last quarter. Sands Capital Management LLC grew its stake in shares of DexCom by 33.9% during the first quarter. Sands Capital Management LLC now owns 4,189,245 shares of the medical device company’s stock worth $2,143,218,000 after purchasing an additional 1,060,655 shares in the last quarter. Clearbridge Investments LLC grew its stake in shares of DexCom by 304.3% during the first quarter. Clearbridge Investments LLC now owns 1,318,079 shares of the medical device company’s stock worth $674,329,000 after purchasing an additional 992,049 shares in the last quarter. Capital Research Global Investors grew its stake in shares of DexCom by 55.2% during the fourth quarter. Capital Research Global Investors now owns 2,374,545 shares of the medical device company’s stock worth $1,275,020,000 after purchasing an additional 844,916 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of DexCom during the fourth quarter worth $410,670,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities analysts recently commented on DXCM shares. Morgan Stanley lowered their target price on shares of DexCom from $91.00 to $83.00 and set an “equal weight” rating for the company in a research note on Friday, July 29th. Wells Fargo & Company decreased their price objective on shares of DexCom from $144.00 to $102.00 in a research note on Friday, July 29th. Robert W. Baird decreased their price objective on shares of DexCom from $115.00 to $97.00 in a research note on Friday, July 29th. BTIG Research decreased their price objective on shares of DexCom from $135.00 to $105.00 and set a “buy” rating for the company in a research note on Friday, June 24th. Finally, Citigroup decreased their price objective on shares of DexCom from $105.00 to $100.00 in a research note on Friday, July 29th. Two research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $115.23.
Insider Buying and Selling
DexCom Trading Down 1.0 %
NASDAQ DXCM opened at $90.09 on Monday. The stock has a market capitalization of $35.37 billion, a P/E ratio of 187.69, a P/E/G ratio of 3.64 and a beta of 1.03. DexCom, Inc. has a 52-week low of $66.89 and a 52-week high of $164.86. The firm has a 50-day moving average price of $85.55 and a 200 day moving average price of $91.86. The company has a quick ratio of 4.30, a current ratio of 4.72 and a debt-to-equity ratio of 0.87.
DexCom (NASDAQ:DXCM – Get Rating) last posted its quarterly earnings results on Thursday, July 28th. The medical device company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.02). The firm had revenue of $696.20 million for the quarter, compared to analysts’ expectations of $709.33 million. DexCom had a return on equity of 11.79% and a net margin of 7.47%. The company’s revenue for the quarter was up 17.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.19 earnings per share. Equities research analysts expect that DexCom, Inc. will post 0.79 EPS for the current year.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.
- Get a free copy of the StockNews.com research report on DexCom (DXCM)
- Kroger’s is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.